Safety and outcomes of open-label deferasirox iron chelation therapy for mucormycosis
B Spellberg, D Andes, M Perez, A Anglim… - Antimicrobial agents …, 2009 - Am Soc Microbiol
B Spellberg, D Andes, M Perez, A Anglim, H Bonilla, GE Mathisen, TJ Walsh, AS Ibrahim
Antimicrobial agents and chemotherapy, 2009•Am Soc MicrobiolWe sought to describe the safety profile of open-label, adjunctive deferasirox iron chelation
therapy in eight patients with biopsy-proven mucormycosis. Deferasirox was administered
for an average of 14 days (range, 7 to 21) at 5 to 20 mg/kg of body weight/day. The only
adverse effects attributable to deferasirox were rashes in two patients. Deferasirox treatment
was not associated with changes in renal or liver function, complete blood count, or
transplant immunosuppressive levels. Thus, deferasirox appears safe as an adjunctive …
therapy in eight patients with biopsy-proven mucormycosis. Deferasirox was administered
for an average of 14 days (range, 7 to 21) at 5 to 20 mg/kg of body weight/day. The only
adverse effects attributable to deferasirox were rashes in two patients. Deferasirox treatment
was not associated with changes in renal or liver function, complete blood count, or
transplant immunosuppressive levels. Thus, deferasirox appears safe as an adjunctive …
Abstract
We sought to describe the safety profile of open-label, adjunctive deferasirox iron chelation therapy in eight patients with biopsy-proven mucormycosis. Deferasirox was administered for an average of 14 days (range, 7 to 21) at 5 to 20 mg/kg of body weight/day. The only adverse effects attributable to deferasirox were rashes in two patients. Deferasirox treatment was not associated with changes in renal or liver function, complete blood count, or transplant immunosuppressive levels. Thus, deferasirox appears safe as an adjunctive therapy for mucormycosis.
American Society for Microbiology